Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Contrave Launch Raises Hopes For Korean Obesity Market Growth

This article was originally published in PharmAsia News

Executive Summary

Following the successful debut of Arena's Belviq in 2015, Orexigen's Contrave, which will be released in South Korea in the second quarter through its partner Kwang Dong Pharm, is set to boost the domestic obesity treatment market which had been depressed since the country banned sales of sibutramine-based drugs in 2010.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts